PTHrP is secreted by most cell types. In addition to a paracrine/autocrine role, PTHrP has "intracrine" actions, entering the nuclear compartment under the direction of a classic bipartite nuclear localization signal. In vascular smooth muscle cells, nuclear entry stimulates mitogenesis. In the current study, we sought to more precisely define the regions of PTHrP required for the activation of mitogenesis in vascular smooth muscle cells. PTHrP deletion mutants missing large regions [i.e. the signal peptide, N terminus (1-36), mid region (38 -86), nuclear localization signal, C terminus (108 -139), or combinations of the above] were expressed in A-10 vascular smooth muscle cells. The consequences on nuclear localization and proliferation were examined. Deletion of the nuclear localization signal prevented nuclear entry and slowed proliferation. Deletion of the highly conserved N terminus or mid region had no impact on nuclear localization or on proliferation. Deletion of the C terminus had no deleterious effect on nuclear localization but dramatically reduced proliferation. Thus, the nuclear localization signal is both necessary and sufficient for nuclear localization of PTHrP. In contrast, activation of proliferation in vascular smooth muscle cells requires both an intact nuclear localization signal and an intact C terminus. Whereas the nuclear localization signal is required for nuclear entry, the C terminus may serve a transactivating function to stimulate mitogenesis once inside the nucleus of vascular smooth muscle cells. (Endocrinology 142:  4096 -4105, 2001) 
liferation. Deletion of the highly conserved N terminus or mid region had no impact on nuclear localization or on proliferation. Deletion of the C terminus had no deleterious effect on nuclear localization but dramatically reduced proliferation. Thus, the nuclear localization signal is both necessary and sufficient for nuclear localization of PTHrP. In contrast, activation of proliferation in vascular smooth muscle cells requires both an intact nuclear localization signal and an intact C terminus. Whereas the nuclear localization signal is required for nuclear entry, the C terminus may serve a transactivating function to stimulate mitogenesis once inside the nucleus of vascular smooth muscle cells. (Endocrinology 142: 4096 -4105, 2001) P THrP IS A UBIQUITOUSLY expressed protein that regulates cellular and/or organ growth, development, migration, differentiation, survival, calcium ion transport, and other physiological and developmental processes (1) (2) (3) (4) . These effects are accomplished in part by paracrine and autocrine actions of the several PTHrP-secreted forms on a growing number of cell surface receptors. The secretory forms of PTHrP include N-terminal, mid region, and Cterminal forms (1) (2) (3) (4) (5) . These several secretory forms are the end result of the posttranslational processing of the initial PTHrP translation products at multibasic amino acid clusters or monomers (Fig. 1 ) by prohormone processing enzymes present within the regulated and constitutive secretory pathways (5, 6) . Entry into the secretory pathway is initiated at the endoplasmic reticulum as a consequence of the interaction of a conventional signal peptide with docking molecules on the cytoplasmic side of the endoplasmic reticulum compartment.
In addition to these widely recognized and accepted paracrine/autocrine actions, a novel mechanism of action for PTHrP is being increasingly recognized (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . In this scenario, PTHrP enters the nuclear compartment under the direction of a classic bipartite nuclear and/or nucleolar localization signal, collectively referred to herein as a nuclear/ nucleolar localization signal (NLS). This NLS is composed of multibasic amino acids in the 88 to 106 region of the peptide (Fig. 1) . Interestingly, this NLS constitutes one of the same multibasic regions that serves as a prohormone convertase cleavage site when PTHrP is contained within the secretory compartment (5) . The functional consequences of nuclear entry by PTHrP that have been observed to date include the regulation of proliferation and/or apoptosis in vascular smooth muscle (VSM) cells and chondrocytes, respectively (8 -10) . These nuclear actions of PTHrP have been termed intracrine to distinguish them from the paracrine and autocrine effects described above. In A-10 VSM cells, for example, endogenous PTHrP is present in the nucleus of a small minority (0.13%) of cells, whereas in the remaining 99.87%, it is principally extranuclear (10) .
Data from several laboratories document that nuclear targeting results from at least two structural features in the PTHrP molecule and may occur via several cellular pathways. First, as noted above, there is a requirement for the NLS. Henderson and coworkers (8) have demonstrated that the bipartite NLS of PTHrP is necessary for the nuclear/ nucleolar appearance of PTHrP, and we have confirmed these observations (10) . Moreover, the NLS of PTHrP is able to drive the nuclear localization of a heterologous protein, ␤-galactosidase (8). Lam and collaborators (11) have indicated that the nuclear transport process is regulated in part by the phosphorylation status of the cyclin-dependent kinase site, Thr 85 , with phosphorylation preventing nuclear entry. Second, there must be a mechanism for the peptide to avoid entry into the secretory pathway after translation so that it is free to traffic to the nucleus. Increasing evidence indicates that the structural feature in the PTHrP molecule that permits this option is the availability of multiple translational initiation sites (7, 16, 17) . A standard AUG codon drives the translation of a molecule with a full and normally functioning signal peptide that directs the precursor into the endoplasmic reticulum. However, alternative CUG and GUG translational initiation sites have been demonstrated downstream of the conventional AUG. These additional translational start sites are positioned within the signal peptide. Translational initiation at these sites thus appears to disrupt the function of the signal peptide, allowing the nascently translated peptide to remain within the cytosol, where, under the direction of the NLS, it enters the nucleus. Third, there is also evidence that PTHrP, once secreted, is able to reenter the cell, perhaps (although this is controversial) via one of the several PTH/PTHrP receptors (12, 14, 15, 18) , and from there gain entry into the nuclear compartment through as yet undefined mechanisms.
Although it seems clear that the nuclear entry of PTHrP is associated with cellular proliferative and/or antiapoptotic responses, it remains unknown how PTHrP may accomplish these effects. One group has suggested that PTHrP may interact with mRNA in the nucleolus (14) , perhaps influencing the cell cycle. It also is possible that PTHrP could interact directly with DNA as a transcription factor, although evidence for this is lacking. It is further possible that PTHrP may interact with as yet unidentified nuclear proteins that may mediate or transactivate its nuclear effects. This area is particularly interesting and as yet poorly understood, in part because there is little in the way of a normal paradigm or example that an investigator might use as a model.
We have been particularly interested in the effects of PTHrP in VSM. In the arterial wall, N-terminal PTHrP species interact in a paracrine/autocrine manner with the PTH/ PTHrP receptor to vasodilate arterial smooth muscle via cAMP and nitric oxide pathways (19 -22) . Clemens and collaborators (20, 21) have demonstrated that targeted overexpression of either the PTHrP molecule or its receptor in transgenic mice leads to arterial hypotension. In addition, PTHrP is up-regulated after arterial injury, for example, after angioplasty and in atherosclerotic disease (23) (24) (25) (26) . It has been suggested that the proliferative effects of PTHrP, mediated by the nuclear entry and action of PTHrP in an intracrine manner, may participate in the cascade of VSM cell proliferation, migration, and matrix synthesis characteristic of atherosclerosis and of vascular restenosis after angioplasty (27, 28) .
In this report, we have used the VSM system as a model to further explore the mechanism of action through which PTHrP drives proliferation after nuclear entry. We were specifically interested in defining the other structural elements, in addition to the NLS, required to drive VSM proliferation. To accomplish this, we have prepared signal peptide deletion mutants that are unable to exit the cell via the secretory pathway, NLS deletion mutants that are unable to enter the nucleus, a variety of deletion mutants affecting other regions of the molecule, and combinations of these mutants, and introduced them into the VSM cell line, A-10, to examine the consequences on PTHrP intracellular trafficking and PTHrPregulated VSM proliferation. Using these approaches, we demonstrate that the NLS is necessary and sufficient to drive the nuclear entry of PTHrP. In contrast, the NLS is necessary but not sufficient to induce mitogenesis in VSM cells, and it requires an additional component of the PTHrP molecule. Interestingly, and unexpectedly, we demonstrate that the highly conserved N-terminal and mid region portions of the PTHrP molecule are not important, whereas the less highly conserved C-terminal region (108 -139) of the peptide is necessary, and with the NLS sufficient, for the activation of proliferation in VSM.
Materials and Methods

Construction of PTHrP mutants
The constructs shown in Fig. 1 were generated by in vitro site-directed mutagenesis as described previously (10) using the cDNA for human PTHrP(Ϫ36/ϩ139) cloned into plasmid pGEM-3 as an initial template. All of the constructs begin with a codon encoding methionine to allow translation. Each has an epitope tag at the C terminus corresponding to human influenza hemagglutinin (HA) for immunocytochemical detection. Each contains the 3Ј untranslated region (UTR) of human ␤-globin for stabilization of the mRNA (to replace the native PTHrP 3Ј-UTR AUUUA instability motif that accelerates mRNA degradation) and to provide transcriptional termination, polyadenylation, and splicing signals. Confirmation of the sequences was accomplished by DNA sequencing. The constructs were then subcloned in the pLJ vector (10) and transfected into A10 cells as described below.
In vitro transcription and translation
To assess the in vitro transcription and translation efficiency of the different mutants of PTHrP, 1 g of each construct in pGEM-3 plasmid was transcribed and translated in a transcription-and translationcoupled rabbit reticulocyte lysate system (Promega Corp., Madison, WI) according to the manufacturer's instructions. Translation products, labeled with [ 3 H]lysine, were analyzed by SDS-PAGE in a 10 to 20% polyacrylamide Tris-glycine gel and then examined using autoradiography.
Cell culture and transfections
The VSM cell line A10 derived from embryonic rat thoracic aorta was purchased from the American Type Culture Collection (Rockville, MD). Cells were cultured in DMEM containing 4.5 g/liter glucose, 10% FBS, 100 U/ml penicillin, 100 g/ml streptomycin, and 2 mm l-glutamine. Twenty-four hours before transfection, A10 cells were plated in six-well plates at a density of 1.5 ϫ 10 5 /well. Transfections were carried out in serum-free medium with 1 g of each plasmid and 10 l of lipofectamine (Life Technologies, Inc., Gaithersburg, MD) for 6 h at 37 C. For transient transfections, after 24 h of recovery cells were replated on glass chamber slides (LabTek, Nalge Nunc International, Naperville, IL) and immunostained 48 h later (see below). Stably transfected clones were selected by treatment with 250 g/ml geneticin (G418, Life Technologies, Inc.). Five to 12 individual clones for each construct were selected, expanded, and analyzed for PTHrP construct expression as described below. Clones were grown continuously in the presence of 250 g/ml G418.
RNase protection assay
Three clones for each construct were selected on the basis of similar expression of mRNA, assessed by RNase protection assay as shown in Fig. 4 . Briefly, 20 g of total RNA from each clone, isolated with Trizol reagent (Life Technologies, Inc.), was hybridized overnight at 55 C with a 32 P-labeled antisense cRNA probe that protected a 230-bp EcoRI fragment of the 3Ј UTR of human ␤-globin mRNA. As an internal control, an antisense cRNA probe recognizing rat cyclophilin was used (Ambion, Inc., Austin, TX). RNase-protected fragments were resolved on 6% polyacrylamide-urea gels and autoradiographed.
PTHrP immunoradiometric assay
PTHrP secreted from A10 cells stably transfected with the different PTHrP constructs was measured in 24-h conditioned medium obtained at confluence using a two-site immunoradiometric assay (IRMA) specific for PTHrP(1-36) (6, 10, 29, 30). The detection limit of the assay is 0.5 pm. For measurement of PTHrP in cell extracts, cells were plated on 100-mm culture plates. At confluence, cells were washed with PBS at room temperature and then resuspended on ice in PBS containing 1% Igepal CA-630 (Sigma, St. Louis, MO), 0.5% sodium deoxycholate, 0.1% SDS, 100 g/ml phenylmethylsulfonyl fluoride, 45 g/ml aprotinin, and 1 mm sodium orthovanadate. They were sonicated three times for 1 min, incubated on ice for 60 min, and then centrifuged at 10,000 ϫ g for 10 min at 4 C. The supernatant representing the cell extract was assayed for PTHrP immunoreactivity using the PTHrP(1-36) IRMA described above. Protein was measured according to the method of Bradford (31), and results are expressed as picomoles per milligram of extract protein.
Fluorescent immunocytochemistry
Transfected or control A-10 cells growing in glass chamber slides were fixed 48 h after plating with 4% paraformaldehyde in PBS for 20 min at room temperature and permeabilized with 0.2% Triton X-100 in PBS for 10 min at room temperature. After 1 h of exposure to blocking buffer (3% normal goat serum, 0.1% BSA, 0.1% Tween-20 in PBS), cells were incubated for 1 h at room temperature with mouse monoclonal anti-HA (HA.11, Covance, Richmond, CA), diluted 1:250 in blocking buffer and then for 1 h at room temperature with a fluorescein isothiocyanate-conjugated antimouse IgG secondary antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), and diluted 1:100 in blocking buffer. After final washes, cells were mounted in ProLong antifade mounting medium (Molecular Probes, Inc., Eugene, OR) and visualized with a Nikon (Tokyo, Japan) FX fluorescence microscope.
Cell counting
Cells were plated into 24-well plates at a density of 10 4 /well. They were trypsinized on the days indicated in Fig. 6 and counted by hemocytometer (10) .
Statistics
Statistical analysis was performed using one-way ANOVA with the Student-Newman-Keuls modification. All values are expressed as means Ϯ sem. P values Յ 0.05 were considered significant.
Results
The NLS is necessary and sufficient for the nuclear appearance of PTHrP in VSM
To fully define the structural requirements for nuclear entry in VSM, we transiently transfected A-10 VSM cells with the 11 constructs depicted in Fig. 1 and examined these cells for evidence of nuclear or secretory pathway presence of PTHrP. We used the influenza HA epitope tag for detection, because the critical epitopes for many PTHrP antisera had been deleted in many of the constructs. As is clear from Fig.  2 (WT), and in confirmation of the results of Massfelder, Henderson, and others (7) (8) (9) (10) (11) (12) , in the presence of an intact signal peptide the majority of PTHrP immunoreactivity is found within the secretory pathway. In contrast, when the signal peptide is deleted (⌬SP constructs in Fig. 2 ), there is a marked and dramatic increase in the amount of PTHrP observed within the nucleus. This nuclear appearance has a diffuse pattern. Importantly, nuclear appearance does not require the presence of any other region of the PTHrP molecule, because deletion of every other region of the molecule-N-terminal, mid, and C-terminal regions-does not negate the nuclear presence of PTHrP. The one exception to this rule is the construct in which both the NLS and the signal peptide were deleted (Fig. 2 , ⌬SP/⌬NLS). In this construct, there appears to be some nuclear staining. The reasons for this are unclear.
Two of the constructs, ⌬SP/⌬(38 -86)/⌬(108 -139) and ⌬SP/⌬(1-79)/⌬(108 -139), demonstrated no HA immunofluorescence ( Figs. 1 and 2 ). Given their marked truncation, it seemed possible that these constructs were not translated. To test this possibility, the complete panel of constructs was examined by in vitro transcription and translation using a [ 3 H]lysine reticulocyte lysate system. As is shown in Fig. 3 , this presumption proved to be correct: whereas each of the other constructs was efficiently translated in vitro, these two constructs showed no evidence of translation. These two constructs, therefore, were noninformative.
The C terminus of PTHrP is required for the induction of proliferation in VSM cells
The results described above, although not previously demonstrated in VSM, were largely predictable from the work of Henderson and colleagues (8) in COS cells. The primary goal of the current project was to determine which regions of the peptide in addition to the NLS, if any, are required for the induction of proliferation in VSM cells. To determine the effects of the various constructs in Fig. 1 on cellular proliferation, the constructs were stably transfected into A-10 VSM cells. Because most of the epitopes for available PTHrP antisera had been deleted in these constructs, selection of clones by PTHrP immunodetection methods was impossible. Therefore, we selected clones based on levels of constructderived RNA expression. Because each construct contained an identical 3Ј end containing a portion of the 3Ј PTHrP UTR spliced to the ␤-globin 3Ј end, we selected a single RNA probe encoding this PTHrP-␤-globin 3Ј region. As shown in Fig. 4 , three clones representing each of the 11 constructs were selected based on comparable levels of PTHrP-␤-globin mRNA expression. Confirmation that the peptide was indeed translated and secreted was performed by IRMA of conditioned medium derived from each of the constructs in Fig. 1 . As expected, the signal peptide-intact constructs secreted easily measurable quantities of PTHrP into their conditioned medium (Fig. 5) , whereas the signal peptide-deletion mutants secreted no measurable peptide. That these other, signal peptide-deleted constructs did indeed produce PTHrP peptide is clear from information described below.
To confirm that the intracellular localization of the stably transfected constructs was comparable to that observed using the transiently transfected constructs shown in Fig. 2 , we also examined the cellular distribution of the HA epitopetagged PTHrP constructs in the stably transfected clones. Although less intense than that observed in the transiently expressing cells, reflecting the lower level of expression in the stably, compared with the transiently, transfected A-10 cells, the cellular distribution of expression of the stable constructs was comparable to that of the transiently transfected A-10 cells shown in Fig. 2 . An example is shown in Fig. 6 . As can be seen in this figure, the distribution of PTHrP-HA immunoreactivity observed using the stable ⌬SP construct was similar to that observed with the same construct transfected transiently (Fig. 2) . Moreover, the large proportion of nuclear targeted cells, also observed with all of the other signal peptide-deleted constructs, both stable and transient, is apparent in this low-power photomicrograph.
Using these stably transfected A-10 clones, we were able to evaluate growth patterns of multiple clones derived from each construct. As is shown in Fig. 7 , the growth rates of the various clones were dramatically different. Fig. 7A shows the cell numbers as a function of time for untransfected A-10 cells and for vector-transfected A-10 cells. The growth rates of these two types of controls were indistinguishable, and in the other three panels they have been combined into a single control group. As shown in Fig. 7B , the A-10 cells expressing the constructs in which the NLS had been deleted (⌬NLS and ⌬SP/⌬NLS) proliferated at a rate that was approximately 50% slower than that of the control cells, represented by the open symbols. These changes were significantly different, as 
FIG. 4.
RNase protection analysis of the clones stably transfected with the 11 constructs. Multiple clones were selected for each of the stably expressing constructs. They were assessed for mRNA expression of the constructs based on RNase protection using a riboprobe corresponding to the common 3Ј PTHrP/␤-globin UTR of each construct. Cyclophilin is the housekeeping gene control. Three clones expressing comparable ranges of PTHrP/␤-globin mRNA were selected for each construct and studied in further detail.
indicated by the asterisks. In Fig. 7C , the proliferation of cells expressing each of the constructs with both an intact NLS and an intact C terminus was brisk. Interestingly, the rate of proliferation of each of these cell lines was very similar, despite very different apparent quantities of PTHrP within the nucleus (Fig. 2) . This may suggest that the nuclear proliferative response is saturable. In Fig. 7D , the growth curves of the C-terminal deletion constructs are shown. The growth rates of these cell lines are strikingly slower than those of the C terminus-intact constructs shown in Fig. 7C . These results clearly demonstrate that although the NLS is required for nuclear localization, the C terminus in addition to the NLS is required for the activation of the nuclear machinery required for proliferation.
One interpretation of these latter findings could be that the two C-terminal deletion mutants described in Fig. 7D were not efficiently expressed. This seems unlikely, because the immunohistochemical nuclear presence of HA for each of these constructs was comparable. To directly confirm the overexpression of the ⌬SP/⌬(108 -139) construct in A-10 cells at the protein level, we prepared extracts of VSM cells transfected with the various constructs and assayed the extracts for PTHrP(1-36) immunoreactivity using the PTHrP(1-36) IRMA. As shown in Fig. 8 , the level of PTHrP production was comparable in the slowly proliferating cells expressing the C terminus-deleted construct compared with the rapidly proliferating cells expressing the C terminus-intact PTHrP constructs. Thus, the slower proliferation observed in the C terminus-deleted mutants cannot be ascribed to underexpression of PTHrP in cells bearing this construct. These findings make it clear that the C terminus is essential, and together with the NLS sufficient, for the stimulation of cell growth in A-10 cells.
Discussion
Henderson and coworkers (8) initially defined the functional importance of the NLS in PTHrP, showing that it was able to direct a heterologous protein, ␤-galactosidase, to the nucleus of COS cells. This result has since been corroborated by others (7) (8) (9) (10) (11) (12) (13) (14) . We have previously demonstrated that both components of the bipartite NLS are required for the nuclear appearance of PTHrP in VSM cells (10) . Here we demonstrate that although the NLS is both necessary and sufficient for the nuclear localization of PTHrP, it alone is inadequate to stimulate proliferation in VSM. The activation of proliferation in VSM cells requires both the NLS and the C terminus of the molecule.
Lam and collaborators (11, 12) have previously demonstrated that in the absence of phosphorylation of Thr 85 , PTHrP can bind, through its NLS region, to importin ␤ and that both a dephosphorylated state of Thr 85 and direct interaction with importin ␤ are required for nuclear entry. Thus, a novel paradigm describing the regulated access to, and transit through, the nuclear pore complex is emerging. In this regard, the constructs used in the current study in which the mid region was deleted conform nicely to the observations of Lam et al. (11, 12) : in the mid region deletion mutants, there is no Thr 85 and thus presumably no braking mechanism to prevent PTHrP from transiting the nuclear pore complex. Thus, this mid region-deficient construct not Fig. 2 . These findings indicate that in the absence of a signal peptide and an intact NLS, all of the PTHrP appears to be in the nuclear compartment and none appears in the secretory pathway. As described in the text, the remaining constructs also displayed patterns comparable to those observed in the transiently expressing cells shown in Fig. 2 . only entered the nucleus but was sufficient to drive cell proliferation, indicating that the mid region is not requisite for proliferation or for nuclear access.
Several investigators have suggested that the N terminus of PTHrP may be not only involved in the activation of the extracellular domain of the PTH/PTHrP receptor but also may play a role in guiding PTHrP from the extracellular domain into the nucleus (12, 14, 15, 18) . The studies in the current report are surprising, then, in that they clearly demonstrate that the 1-37 region is not required for nuclear access or for the activation of proliferation in VSM cells. These findings do not directly conflict with the secretion/receptormediated internalization hypothesis, but they suggest that if it occurs it is not the only mechanism for nuclear access.
In marked contrast, the C terminus, although nonessential for nuclear entry, is absolutely essential for the stimulation of proliferation, at least in VSM cells. This is consistent with our earlier studies in which NLS deletion mutants failed to drive VSM proliferation, whereas overexpression of the intact wild-type molecule, including the C terminus, stimu-FIG. 7. Growth patterns of the control and PTHrP-expressing constructs. Growth curves in PTHrP-overexpressing A-10 cells have previously (10) been shown to reflect proliferation as assessed using [ 3 H]thymidine. The symbol keys in each panel show the constructs used, and the number of growth curves examined for each construct are shown in parentheses. For each clonal line shown, three separate clones derived from each construct were used (only two clones for the vector control pLJ in A), and triplicate growth curves were obtained. Thus, a minimum of 18 data points are used for each data point shown. Error bars indicate SEM, and statistical significance is indicated in the symbol keys adjacent to the label of each construct. NS, Not significant; *, P Ͻ 0.05 compared with control cell lines in A as assessed using ANOVA; #, P Ͻ 0.05 compared with ⌬SP in C; §, P Ͻ 0.05 compared with ⌬SP/⌬(1-37) in C. A, Growth curves for the vector alone and untransfected A-10 cells. These two controls are comparable and are combined in each of the subsequent panels and referred to as A-10/pLJ. B, Growth curves of the two NLS-deleted constructs compared with the controls. Note that growth is reduced by approximately 50% for each of these constructs and that these results are significantly different from those in the controls. C, Results for each construct that has an intact NLS as well as an intact C terminus. These constructs are either wild-type PTHrP or have deletions of the SP, the N-terminal region, the mid region, or combinations of the above. Each of these constructs comparably and dramatically stimulates the growth of A-10 cells, regardless of the presence or absence of the SP, the N terminus, or the mid region. D, Growth curves of the constructs that contain an intact NLS but deleted C terminus. Both of these constructs grow at rates no different from the controls but strikingly slower than the C terminus-intact constructs shown in C. These results demonstrate that the SP, N-terminal, and mid region portions of the PTHrP molecule are not required for stimulation of growth, whereas both the NLS and the C terminus are required. lated proliferation (10) . The term proliferation is used advisedly here, for we previously demonstrated not only increases in cell number but also increases in [ 3 H]thymidine incorporation in A-10 cells overexpressing wild-type PTHrP and a decline in [ 3 H]thymidine incorporation in the NLS deletion mutants (10) . Moreover, we have also demonstrated that, in aortic VSM cells of the PTHrP knockout mouse, proliferation in vivo using bromodeoxyuridine is reduced compared with that observed in wild-type aortic VSM cells (10) .
These results are of interest for several reasons. First, although it seems clear that the C terminus of PTHrP [e.g. PTHrP(107-139) or PTHrP(107-111), so called osteostatin] is likely to be a mature secretory form of the peptide, and although this peptide appears to have biological effects in some cell systems such as osteoblasts and osteoclasts when added to the culture medium of these cells (32) (33) (34) (35) , there is controversy regarding the reproducibility and biological relevance of these findings. These considerations, together with the current findings, raise the possibility that the C terminus of PTHrP may be as important, or more important, as a transactivating domain for nuclear effects of PTHrP than as a discrete secretory form of the peptide. Second, they suggest that there may be specific nuclear protein or nucleic acid targets for this region of the peptide. Third, they suggest that the results of experiments exploring the physiology of the NLS through the use of premature termination codons upstream of the NLS (36) will need to be interpreted in light of the deletion of the C terminus as well. In support of the concept that the C terminus plays a regulatory role in cell physiology, there appear to be potential phosphorylation sites in the 107-139 region of the peptide that could be important in regulating the cellular actions of the peptide (Fig.  9) . Clearly, further fine mapping of this region will be critical to identify specific residues or regions required for the activation of proliferation. Similarly, this region may be a reasonable bait for two-hybrid studies aimed at identifying the potential nuclear protein partners of PTHrP. Finally, the studies described here used human PTHrP constructs in murine cells. It will be important to determine whether species-homologous PTHrP constructs and cell lines display these same proliferative associations with the C terminus. For example, does the human C terminus influence proliferation in human VSM cells? Does the murine PTHrP C terminus influence proliferation in murine VSM cells?
To date, functional consequences of the NLS to support a cellular function have been demonstrated only in two cell types: the chondrocyte and the VSM cell. Henderson and coworkers (8, 9) have provided evidence that the NLS is required to prevent serum starvation-induced cell death in chondrocytes, and we have demonstrated that the NLS, and now the C terminus, are requisite for proliferation in VSM cells (10) . The functional consequences described here of C-terminal deletion of PTHrP on proliferation are unique, thus far, to VSM. On the other hand, the presence of PTHrP within the nucleus has been demonstrated in multiple cell types, from chondrocytes and VSM cells to fibroblasts, osteoblasts, mammary epithelial cells, hepatocytes, gonadal cells, and others (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . These observations suggest that functional effects or nuclear PTHrP entry are likely to be more widespread than has been obvious to date. The development of generalized NLS-deleted PTHrP knock-in mice (36) will likely be instructive. Importantly, in the two cell types in which nuclear targeting-associated functions have been identified, the chondrocyte (8, 9 ) and the VSM cell (10), these functional responses (apoptosis vs. proliferation) are quite different. This suggests that the nuclear consequences of PTHrP entry are likely to be cell specific.
Henderson and collaborators (8, 9) as well as others have suggested that when PTHrP enters the nucleus, it is princi-FIG. 8. PTHrP content of A-10 cell extracts. Fig. 3 demonstrates that the SP-intact constructs lead to the presence of PTHrP in the medium, but it does not document PTHrP production from the remaining constructs. To determine whether the SP-deleted constructs also produce PTHrP protein at comparable levels, extracts were prepared representing each of the constructs that contained the PTHrP(1-36) region, and these were assayed for PTHrP immunoreactivity using the PTHrP(1-36) IRMA. The dotted horizontal line indicates the detection limit of the PTHrP IRMA in control cell extracts. As can be seen, A-10 cells contained undetectable concentrations of PTHrP, whereas each of the constructs led to the production of comparable quantities of PTHrP. Importantly, the ⌬SP/⌬(108 -139) construct, which is unable to drive VSM growth, leads to indistinguishable production of PTHrP compared with the remaining growth-stimulating constructs. This, together with comparable expression at the immunohistochemical level, indicates that the failure of the C terminus-deleted constructs to stimulate growth cannot be ascribed to the failure of these proteins to be produced or to their inability to enter the nucleus. FIG. 9 . The C-terminal (107-139) region of PTHrP. The 107-111 TRSAW (Thr-Arg-Ser-Ala-Trp) region is intensely conserved among species (32) (33) (34) (35) . The remainder of the C-terminal region is not highly conserved among species but contains a number of consensus phosphorylation sites of serines and threonines. These serine and threonine residues, although not identically located, are broadly conserved among species in the 107-139 region and may be involved in PTHrP regulation of proliferation in VSM.
pally observed in the nucleolar compartment. In contrast, we and others have observed PTHrP principally in a diffuse nuclear pattern (10 and refs. therein). The reasons for the nuclear vs. nucleolar predominance in these various studies requires clarification. It does not seem to result from the use of different antisera, because PTHrP has been observed in both the nucleus and the nucleolus using HA epitope-tagged constructs (16) as well as the same commercially available PTHrP antisera used by several groups. It does not appear to be attributable to a species difference in the rat vs. the human cDNA sequences, because the sequences of these two constructs are so similar that this would seem unlikely a priori. Indeed, the nuclear and nucleolar patterns have been observed in studies using both the human and rat PTHrP cDNAs (8 -17) . Our presumption, then, is that the pattern may be cell type specific, appearing principally in the nucleus in certain cell types and principally in the nucleolus in other cell types. Clarification of this issue again requires further study.
The observations that the NLS deletion mutants demonstrate slower proliferation than that observed in untransfected and mock-transfected A-10 cells merits attention. First, this independently confirms using new constructs the earlier observations of Massfelder et al. (10) . In addition, because the constructs used in the current study, including wild-type and ⌬NLS constructs, all contained a C-terminal HA epitope tag, these findings indicate that the HA tag does not interfere either with the ability of the C terminus to stimulate proliferation or with nuclear targeting. One is left to speculate as to the mechanisms underlying the reduction in the proliferation rate induced by NLS deletion. One possibility is that the deletion of the NLS does not prevent, and indeed may favor, the secretion of the growth inhibitory, adenylyl cyclaseactivating, N-terminal portion of the molecule, as suggested by Ditmer et al. (37) . Alternatively, it may be that the proteins derived from the ⌬NLS constructs interfere in some dominant-negative fashion with nuclear access or nuclear function of the wild-type PTHrP. Clarification of these issues will require further study. In either case, however, these observations suggest that NLS and/or C-terminal truncated forms of PTHrP may have therapeutic utility in disorders associated with smooth muscle cell proliferation. Examples of conditions in which excessive smooth muscle proliferation yields pathological results are uterine fibroid tumors, prostatic hypertrophy, bronchial asthma, portal hypertension in cirrhosis, pulmonary and systemic arterial hypertension, arteriosclerosis, and vascular restenosis after angioplasty. The possibility that delivery of modified PTHrP constructs may ameliorate, at least in part, some or all of these disorders deserves further investigation. Indeed, Ishikawa and colleagues (26) have recently demonstrated that application of PTHrP to injured arteries in a model of arterial restenosis does indeed dramatically reduce the degree of restenosis after arterial injury.
Finally, it should be noted that the studies described here used forced overexpression of PTHrP in VSM cells. One must wonder whether the results of such studies reflect events occurring when the protein is expressed at physiological levels. Two observations provide reassurance. First, the levels of overexpression are very low, as described in Figs. 5 and 8, with only low picomolar concentrations appearing in the medium of transfected cells. Second, VSM proliferation in PTHrP null mice is slower than that observed in wild-type littermates (10) , suggesting that underexpression has the reverse effect of the overexpression observed here.
In summary, these studies independently demonstrate that nuclear-targeted PTHrP activates proliferation in VSM cells. Importantly and surprisingly, these studies unequivocally indicate that the C terminus of the molecule is critically important in driving the intracrine stimulation of proliferation in VSM cells. This result is surprising because the Cterminal region is the least highly conserved region of the molecule, in contrast to the extremely highly conserved Nterminal and mid region portions of the molecule. These findings suggest that the C-terminal region may serve some sort of transactivating role for nuclear partners of PTHrP and provide an attractive target for two-hybrid strategies aimed at identifying such potential partners. Finally, these studies suggest possible therapeutic potential for NLS-or C terminus-deleted forms of PTHrP.
